Logo Logo
Switch Language to German
Schimanski, Carl Christoph; Kasper, Stefan; Hegewisch-Becker, Susanna; Schroeder, Jan; Overkamp, Friedrich; Kullmann, Frank; Bechstein, Wolf Otto; Voehringer, Matthias; Oellinger, Robert; Lordick, Florian; Heinemann, Volker; Geissler, Michael; Schulz-Abelius, Armin; Bernhard, Helga; Schoen, Michael R.; Greil, Richard; Galle, Peter; Lang, Hauke; Schmidtmann, Irene; Moehler, Markus (2020): Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC). In: Oncoimmunology, Vol. 9, No. 1, 1806680
Full text not available from 'Open Access LMU'.


Resection of colorectal liver metastases (CRLM) is a potential curative treatment for patients with metastatic colorectal cancer (mCRC) with liver-limited disease (LLD). Although long-term survival improved considerably within the last decades, high recurrence rates of 50-75% after resection remain a major challenge.Tecemotide (L-BLP25) is an antigen-specific cancer vaccine inducing immunity against mucin-1 (MUC1). The LICC trial aimed to improve survival in patients with mCRC after R0/R1 resection of CRLM. LICC was a binational, randomized, double-blind, placebo-controlled, multicenter phase 2 study including patients with R0/R1 resected CRLM without evidence of metastatic disease outside the liver. Co-primary endpoints were recurrence-free survival (RFS) and 3-year overall survival (OS) rate, secondary endpoints were RFS and OS in subgroups with different MUC1 expression and safety. In total, 121 patients were 2:1 randomized between Oct 2011 and Dec 2014to receive tecemotide (N=79) or placebo (N=42). Baseline characteristics were well balanced. Median RFS was 6.1 months (95% CI 4.5-8.9) and 11.4 months (95% CI 3.7-21.2) (P= .1754), 3-year OS rate 69.1% and 79.1%, median OS 62.8 months and not reached in the tecemotide vs. placebo arm (P= .2141), respectively. Cox regression models revealed no dependence of RFS or OS on MUC1 expression. The most common tecemotide-related grade 3/4 adverse events were diarrhea, injection site reaction, intestinal perforation, peritonitis and tinnitus (1.3% each). The LICC trial failed to meet its primary endpoints of significantly improving RFS and OS with tecemotide. However, both arms showed unexpectedly long OS. MUC1 expression was not associated with outcome. EudraCT No: 2011-000218-20 Clinical Trial Information: NCT01462513 Financial Support: Merck KGaA, Darmstadt, Germany